Michael Klichinsky
About Michael Klichinsky
Michael Klichinsky is the Chief Scientific Officer at Carisma, a company he co-founded in 2016, known for developing CAR-Macrophages during his doctoral thesis.
Michael Klichinsky Chief Scientific Officer
Michael Klichinsky holds the position of Chief Scientific Officer at Carisma. He has been with the company since its inception, playing a pivotal role in its scientific direction and growth. In this role, he oversees the strategic planning and development of the company's scientific research and innovations, ensuring alignment with Carisma's overall mission and goals.
Michael Klichinsky Co-founded Carisma
Michael Klichinsky co-founded Carisma in 2016. His vision and expertise have been instrumental in establishing the company as a significant player in the field of immunotherapy. As a co-founder, he has helped build and guide the organization's research and development, working towards groundbreaking advancements in cancer treatment.
Michael Klichinsky's Career at Carisma
Michael Klichinsky has held several significant positions at Carisma. From October 2018 to April 2021, he served as Vice President of Discovery, leading efforts to identify and develop new therapeutic targets. Following this role, he became the Senior Vice President of Research from April 2021 to April 2022, continuing to drive the company's research initiatives forward.
Michael Klichinsky Education and Expertise
Michael Klichinsky earned a Doctor of Pharmacy degree from the University of Sciences in Philadelphia, followed by a PhD in Pharmacology from the University of Pennsylvania. During his doctoral studies, he developed CAR-Macrophages under the co-mentorship of Saar Gill and Carl June. This work has significantly contributed to advancements in immunotherapy research, particularly in the development of new cancer treatments.